As of September 30, 2026, NOVONESIS A S carries a market capitalization of 29.50B, placing it among publicly traded companies globally. Its enterprise value stands at 32.52B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 29.50B |
| Enterprise Value | 32.52B |
NOVONESIS A S's next confirmed earnings release is scheduled for February 11, 2027.
| Earnings Date | 2/11/2027 |
As of September 30, 2026, NOVONESIS A S has 466.39M shares outstanding.
| Shares Outstanding | 466.39M |
As of September 30, 2026, NOVONESIS A S trades at a trailing price-to-earnings ratio of 38.14. The price-to-sales ratio is 5.94, and the price-to-book ratio stands at 2.32.
| PE Ratio | 38.14 |
| PS Ratio | 5.94 |
| PB Ratio | 2.32 |
| P/TBV Ratio | 155.69 |
| P/FCF Ratio | 40.09 |
| P/OCF Ratio | 21.20 |
As of September 30, 2026, NOVONESIS A S trades at an EV/EBITDA multiple of 28.96 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 28.96 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. NOVONESIS A S trades at an EV/FCF ratio of 43.88, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 32.52B versus a market cap of 29.50B, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 6.56 |
| EV / EBITDA | 28.96 |
| EV / EBIT | 28.96 |
| EV / FCF | 43.88 |
As of September 30, 2026, NOVONESIS A S maintains a current ratio of 1.53, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.53 |
| Quick Ratio | 0.31 |
| Debt / Equity | 27.91 |
| Debt / EBITDA | 3.16 |
These figures cover the twelve months ended September 30, 2026. The company generates approximately 425,690.00 in revenue per employee across its workforce of 11,641.00, a quick read on workforce productivity versus industry peers.
| Revenue Per Employee | 425,690.00 |
| Employee Count | 11,641.00 |
Over the twelve months ended September 30, 2026, NOVONESIS A S recorded 217.50M in income tax expense. That works out to an effective tax rate of 21.97, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 989.91M, leaving 772.41M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 217.50M |
| Effective Tax Rate | 21.97 |
As of the close on November 16, 2026, NOVONESIS A S's stock has gained approximately 2.75% over the past 52 weeks. The 50-day moving average sits at 67.09, while the 200-day moving average is 62.76.
| 52-Week Price Change | 2.75% |
| 50-Day Moving Average | 67.09 |
| 200-Day Moving Average | 62.76 |
Over the twelve months ended September 30, 2026, NOVONESIS A S generated 4.96B in revenue and converted that into 772.41M in net income, yielding earnings per share of 1.64. EBITDA reached 1.12B, while operating income came in at 1.14B.
| Revenue | 4.96B |
| Gross Profit | 2.79B |
| Operating Income | 1.14B |
| Pretax Income | 989.91M |
| Net Income | 772.41M |
| EBITDA | 1.12B |
| EBIT | 1.12B |
| Earnings Per Share (EPS) | 1.64 |
As of September 30, 2026, NOVONESIS A S holds 527.60M in cash and equivalents against 3.55B in total debt, resulting in a net debt position of 2.53B. Total book value stands at 12.71B, with working capital of 890.51M providing operational flexibility.
| Cash & Cash Equivalents | 527.60M |
| Total Debt | 3.55B |
| Net Debt | 2.53B |
| Equity (Book Value) | 12.71B |
| Book Value Per Share | 27.26 |
| Working Capital | 890.51M |
NOVONESIS A S produced 1.39B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -648.53M in capital expenditures, free cash flow totaled 741.24M - equivalent to 1.59 per share.
| Operating Cash Flow | 1.39B |
| Capital Expenditures | -648.53M |
| Free Cash Flow | 741.24M |
| FCF Per Share | 1.59 |
Over the twelve months ended September 30, 2026, NOVONESIS A S posted a gross margin of 56.32, reflecting its pricing power and cost economics. The operating margin of 23.02 and net profit margin of 15.59 provide insight into operational efficiency.
| Gross Margin | 56.32 |
| Operating Margin | 23.02 |
| Pretax Margin | 19.98 |
| Profit Margin | 15.59 |
| EBITDA Margin | 22.67 |
Over the twelve months ended September 30, 2026, NOVONESIS A S paid dividends of 1.00 per share. The dividend payout ratio of 60.43 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 2.49, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.68, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to NOVONESIS A S shareholders.
| Dividend Per Share | 1.00 |
| Payout Ratio | 60.43 |
| Shareholder Yield | 1.68 |
| FCF Yield | 2.49 |
NOVONESIS A S's most recent stock split took place on December 9, 2011 with a 1:5 split ratio.
| Last Split Date | 12/9/2011 |
| Split Ratio | 1:5 |
As of September 30, 2026, NOVONESIS A S has an Altman Z-Score of 7.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.02 |
Already premium?